Press Releases
Sep. 20, 2016 biOasis Enters Into a License Agreement With Vaccinex Inc
Vancouver, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (“biOasis”), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, today announced it has entered into a License Agreement (the “Agreement”) with Vaccinex Inc. (“Vaccinex”). Under the terms of the Agreement, Vaccinex will have the right to commercialize its… Read more »
Aug. 29, 2016 biOasis Announces Publication of Scientific Paper – Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brains of Animal Model
Vancouver, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced the publication of a peer-reviewed scientific paper detailing the results of an in-vivo study of the treatment of Metastatic HER2+ Breast Cancer brain tumors in an animal… Read more »
Jul. 10, 2016 biOasis Announces the Issuance of an Additional US Patent for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier
Vancouver, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the issuance of a US patent covering a refined subset of fragments found within Melanotransferrin or P97 for the delivery of therapeutic agents to the brain. The U.S.… Read more »
May. 17, 2016 biOasis Technologies Inc. to Present at BIO International Conference in San Francisco on June 7, 2016
biOasis to showcase their Transcend technology for the transport of drugs across the blood-brain barrier (BBB)
Apr. 21, 2016 biOasis Technologies Enters into a License Agreement with Astellas Research Institute of America LLC
Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI)(OTCQB: BIOAF)(the “Company”) announces that it has entered into a License Agreement to collaborate with Astellas Research Institute of America LLC (“Astellas”). The terms of the agreement, for competitive reasons, remain confidential, as do the specific therapeutic targets and work programs. The companies intend to collaborate on the… Read more »
Apr. 8, 2016 biOasis Technologies Inc. Grants Stock Options
Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI)(OTCQB: BIOAF)(the “Company”) announces that pursuant to the Company’s Incentive Stock Option Plan (the “Plan”), it has granted incentive stock options to directors, officers and consultants of the Company to purchase an aggregate of 1,950,000 common shares in the capital stock of the Company. The options are exercisable at… Read more »
Feb. 29, 2016 biOasis Announces Shares for Services Settlement
Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI)(OTCQB: BIOAF)(the “Company”) wishes to announce its intention to issue 125,000 shares for services to a consultant of the Company that provides certain consulting services related to business development and financial advisory services. The issuance of shares for services will represent payment of consulting fees. The consulting agreement… Read more »
Nov. 29, 2015 biOasis Announces the Issuance of a US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier Using Polypeptides Derived From the Transcend Protein Delivery Vector
Vancouver, BC–(Business Wire)– biOasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (“biOasis or the “Company), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (“BBB”), announces the issuance of a US patent covering the delivery of therapeutic agents by using polypeptides from the company’s Transcend BBB delivery vector. biOasis’ Transcend… Read more »
Nov. 11, 2015 biOasis Announces the Issuance of a Key US Patent for the Delivery Through the Blood-Brain Barrier of Therapeutic Antibodies – Inclusive of Trastuzumab – to Treat Her2/neu Brain Metastases
biOasis’ Transcend Platform has shown great utility in pre-clinical animal models to deliver therapeutic compounds into the brain at sufficient levels to reach a therapeutic effect. Without the Transcend delivery vehicle these compounds would otherwise be excluded from the brain due to the presence of the protective blood-brain barrier. The issuance of this patent indicates that compounds, such as in this case Trastuzumab can be, with the help of Transcend, protected under the issuance of a new patent, including for a new therapeutic indication – brain metastases. Trastuzumab coupled to the transport vector Transcend thus offers a potential treatment for this dreadful cancer.
Sep. 29, 2015 biOasis Announces Listing on OTCQB Exchange
Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI)(OTCQB: BIOAF)(the “Company”) wishes to announce that its current listing on the OTCQX will be changing to a listing on the OTCQB. The Company’s trading symbol will remain BIOAF. The Company remains in compliance with all relevant TSX Venture and OTCQB reporting standards and will continue trading on… Read more »